Anna Spagnoli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anna Spagnoli has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
B Boscherini
Department of Pediatrics, Tor Vergata University, Rome, Italy
3 shared publicationsFrancesco Chiarelli
From the ‡Department of Pediatrics, Oregon Health Sciences University, Portland, Oregon 97201, the ¶Research Department, Shriners Hospital for Children, Portland, Oregon 97201, and the ‖Department of Pediatrics, University of Chieti, 66013 Chieti, Italy
2 shared publications- G L Spadoni
Department of Pediatrics, Tor Vergata University, Rome, Italy
2 shared publications Ron G. Rosenfeld
From the ‡Department of Pediatrics, Oregon Health Sciences University, Portland, Oregon 97201, the ¶Research Department, Shriners Hospital for Children, Portland, Oregon 97201, and the ‖Department of Pediatrics, University of Chieti, 66013 Chieti, Italy
2 shared publicationsA M Pasquino
Departments of Pediatrics, Tor Vergata University and La Sapienza University, Rome, Italy
1 shared publicationBrunetto Boscherini
Department of Paediatrics, Tor Vergata University, Rome, Italy
1 shared publication
Latest Publications
- Open Access
- 1 February 2001
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 276 (8) , 5533-5540
Antiproliferative Effects of Insulin-like Growth Factor-binding Protein-3 in Mesenchymal Chondrogenic Cell Line RCJ3.1C5.18
- 1 February 2001
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 276 (8) , 5533-5540
Open AccessAntiproliferative Effects of Insulin-like Growth Factor-binding Protein-3 in Mesenchymal Chondrogenic Cell Line RCJ3.1C5.18
- 1 November 1999
- Published by Wiley in Clinical Endocrinology
- Vol. 51 (5) , 587-596
Evaluation of the components of insulin-like growth factor (IGF)-IGF binding protein (IGFBP) system in adolescents with type 1 diabetes and persistent microalbuminuria: relationship with increased urinary excretion of IGFBP-3 18 kD N-terminal fragment
OBJECTIVE IGFs and their binding proteins (IGFBPs) have an important role in controlling glucose homeostasis and there is evidence to support their involvement in complications related to type I diabetes. The aim of this study was to evaluate the components of the IGF‐IGFBP system in adolescents with type 1 diabetes that had developed persistent microalbuminuria (MA). DESIGN AND PATIENTS A cohort of 49 adolescents with type 1 diabetes were enrolled in the study. Patients were evaluated at baseline and 1 year later (follow‐up). Twenty‐six patients with persistent urinary albumin excretion (UAE) of more than 20 μg/min/1.73 m2 (21.6–109.4 μg/min/1.73 m2) in three different nocturnal urinary collections within 6 months were considered to have MA (baseline mean: 41.9 ± 22.3 μg/min/1.73 m2; follow‐up: 55.9 ± 24.8 μg/min/1.73 m2). Twenty‐three patients with UAE of less than 20 μg/min/1.73 m2 were assigned to the group without MA (baseline mean: 8.6 ± 3.7 μg/min/1.73 m2; follow‐up: 11.8 ± 4.2 μg/min/1.73 m2). Fasting serum levels of IGFBP‐1, IGFBP‐2, IGFBP‐3, IGF‐I and free‐IGF‐I were determined using appropriate immunoenzymatic, radioimmuno‐ or immunoradiometric assays. Overnight 12‐h urinary collections were obtained and assessed for IGFBP‐3 levels, determined by immunoradiometric assay. Urinary and circulating immunoreactive IGFBP‐3 forms were determined by Western‐immunoblotting (WIB) analysis using a specific polyclonal antibody and monoclonal antibodies directed against N‐terminal and C‐terminal epitopes of IGFBP‐3. IGFBP‐3 protease activity was determined using protease assay and by analysis of the intact over the fragmented immunoreactive forms of IGFBP‐3 determined by WIB analysis. RESULTS Patients with MA showed higher levels of urinary IGFBP‐3 (649 ± 440 ng/h/m2) than patients without MA (398 ± 229 ng/h/m2; P < 0.05). Urinary levels of IGFBP‐3 were directly correlated to UAE (P < 0.001). WIB analysis, using monoclonal antibodies directed against characterized N‐terminal and C‐terminal IGFBP‐3 epitopes, determined that the immunoreactive form of IGFBP‐3 found in urine from patients with diabetes was an N‐terminal 18 kD fragment. Serum IGFBP‐3 levels were lower in patients with MA (baseline: 3613 ± 598 μg/l; one year follow‐up: 3347 ± 624 μg/l) compared with patients without MA (baseline: 4701 ± 1484 μg/l; follow‐up: 4177 ± 703 μg/l; P < 0.001). In serum from patients with MA, intact IGFBP‐3 was decreased, as indicated by WIB analysis. Conversely, IGFBP‐3 proteolysis was increased in patients with MA (baseline: 131 ± 21% of control; follow‐up: 130 ± 23% of control), compared to patients with normal UAE (baseline: 96 ± 23% of control; follow‐up: 96 ± 14% of control; P < 0.001). Serum IGFBP‐3 protease activity was directly correlated to urinary IGFBP‐3 levels (P < 0.001). Serum IGFBP‐1 levels were increased in patients with MA (baseline: 36 ± 20 μg/l; follow‐up: 36 ± 17 μg/l) compared with patients without MA (baseline: 17 ± 11 μg/l; follow‐up: 18 ± μg/l; P < 0.05). Serum IGFBP‐2 levels were also persistently increased in patients with MA (baseline: 503 ± 134 μg/l; follow‐up: 484 ± 166 μg/l) compared with patients without MA (baseline: 375 ± 83 μg/l; follow‐up: 390 ± 85 μg/l; P < 0.05). On the other hand, free IGF‐I levels were decreased in patients with MA (baseline: 2.3 ± 1.5 μg/l; follow‐up: 2.5 ± 1.4 μg/l) compared with those patients without MA (baseline: 4.1 ± 2.1 μg/l; follow‐up: 4.0 ± 2.2 μg/l; P < 0.05). CONCLUSIONS It has been demonstrated that in adolescents with type 1 diabetes and persistent microalbuminuria, the IGF‐IGFBP system is deranged. A urinary 18 kD N‐terminal IGFBP‐3 fragment has been characterized that, in patients with microalbuminuria, correlates with urinary albumin excretion and with serum IGFBP‐3 protease activity. The mechanisms behind these changes remain unclear, but alterations in circulating levels of IGFBPs may alter IGF‐I bioactivity. Determination of urinary levels of IGFBP‐3 might be supportive to the measurement of urinary albumin as an early sign of diabetic nephropathy.
- 1 November 1999
- Published by Wiley in Clinical Endocrinology
- Vol. 51 (5) , 587-596
Evaluation of the components of insulin-like growth factor (IGF)-IGF binding protein (IGFBP) system in adolescents with type 1 diabetes and persistent microalbuminuria: relationship with increased urinary excretion of IGFBP-3 18 kD N-terminal fragment
OBJECTIVE IGFs and their binding proteins (IGFBPs) have an important role in controlling glucose homeostasis and there is evidence to support their involvement in complications related to type I diabetes. The aim of this study was to evaluate the components of the IGF‐IGFBP system in adolescents with type 1 diabetes that had developed persistent microalbuminuria (MA). DESIGN AND PATIENTS A cohort of 49 adolescents with type 1 diabetes were enrolled in the study. Patients were evaluated at baseline and 1 year later (follow‐up). Twenty‐six patients with persistent urinary albumin excretion (UAE) of more than 20 μg/min/1.73 m2 (21.6–109.4 μg/min/1.73 m2) in three different nocturnal urinary collections within 6 months were considered to have MA (baseline mean: 41.9 ± 22.3 μg/min/1.73 m2; follow‐up: 55.9 ± 24.8 μg/min/1.73 m2). Twenty‐three patients with UAE of less than 20 μg/min/1.73 m2 were assigned to the group without MA (baseline mean: 8.6 ± 3.7 μg/min/1.73 m2; follow‐up: 11.8 ± 4.2 μg/min/1.73 m2). Fasting serum levels of IGFBP‐1, IGFBP‐2, IGFBP‐3, IGF‐I and free‐IGF‐I were determined using appropriate immunoenzymatic, radioimmuno‐ or immunoradiometric assays. Overnight 12‐h urinary collections were obtained and assessed for IGFBP‐3 levels, determined by immunoradiometric assay. Urinary and circulating immunoreactive IGFBP‐3 forms were determined by Western‐immunoblotting (WIB) analysis using a specific polyclonal antibody and monoclonal antibodies directed against N‐terminal and C‐terminal epitopes of IGFBP‐3. IGFBP‐3 protease activity was determined using protease assay and by analysis of the intact over the fragmented immunoreactive forms of IGFBP‐3 determined by WIB analysis. RESULTS Patients with MA showed higher levels of urinary IGFBP‐3 (649 ± 440 ng/h/m2) than patients without MA (398 ± 229 ng/h/m2; P < 0.05). Urinary levels of IGFBP‐3 were directly correlated to UAE (P < 0.001). WIB analysis, using monoclonal antibodies directed against characterized N‐terminal and C‐terminal IGFBP‐3 epitopes, determined that the immunoreactive form of IGFBP‐3 found in urine from patients with diabetes was an N‐terminal 18 kD fragment. Serum IGFBP‐3 levels were lower in patients with MA (baseline: 3613 ± 598 μg/l; one year follow‐up: 3347 ± 624 μg/l) compared with patients without MA (baseline: 4701 ± 1484 μg/l; follow‐up: 4177 ± 703 μg/l; P < 0.001). In serum from patients with MA, intact IGFBP‐3 was decreased, as indicated by WIB analysis. Conversely, IGFBP‐3 proteolysis was increased in patients with MA (baseline: 131 ± 21% of control; follow‐up: 130 ± 23% of control), compared to patients with normal UAE (baseline: 96 ± 23% of control; follow‐up: 96 ± 14% of control; P < 0.001). Serum IGFBP‐3 protease activity was directly correlated to urinary IGFBP‐3 levels (P < 0.001). Serum IGFBP‐1 levels were increased in patients with MA (baseline: 36 ± 20 μg/l; follow‐up: 36 ± 17 μg/l) compared with patients without MA (baseline: 17 ± 11 μg/l; follow‐up: 18 ± μg/l; P < 0.05). Serum IGFBP‐2 levels were also persistently increased in patients with MA (baseline: 503 ± 134 μg/l; follow‐up: 484 ± 166 μg/l) compared with patients without MA (baseline: 375 ± 83 μg/l; follow‐up: 390 ± 85 μg/l; P < 0.05). On the other hand, free IGF‐I levels were decreased in patients with MA (baseline: 2.3 ± 1.5 μg/l; follow‐up: 2.5 ± 1.4 μg/l) compared with those patients without MA (baseline: 4.1 ± 2.1 μg/l; follow‐up: 4.0 ± 2.2 μg/l; P < 0.05). CONCLUSIONS It has been demonstrated that in adolescents with type 1 diabetes and persistent microalbuminuria, the IGF‐IGFBP system is deranged. A urinary 18 kD N‐terminal IGFBP‐3 fragment has been characterized that, in patients with microalbuminuria, correlates with urinary albumin excretion and with serum IGFBP‐3 protease activity. The mechanisms behind these changes remain unclear, but alterations in circulating levels of IGFBPs may alter IGF‐I bioactivity. Determination of urinary levels of IGFBP‐3 might be supportive to the measurement of urinary albumin as an early sign of diabetic nephropathy.
- 1 December 1995
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 80 (12) , 3668-3676
Characterization of a low molecular mass form of insulin-like growth factor binding protein-3 (17.7 kilodaltons) in urine and serum from healthy children and growth hormone (GH)-deficient patients: relationship with GH therapy.
The insulin-like growth factor binding proteins (IGFBPs) are the carriers for insulin-like growth factor (IGF0-I and IGF-II. IGFBP-3 is GH-dependent and circulates associated with IGFs and an acid-labile subunit to form a 150-kilodalton (kDa) complex. In human serum, two immunoreactive molecular weight forms of IGFBP-3 have been identified. In human urine, radioimmunoassayable levels of IGFBP-3 have been detected. The objectives of this study were to characterize the molecular weight forms of IGFBP-3 in urine and serum of healthy children and adults and in children with GH deficiency (GHD), to quantify the urinary molecular weight forms of IGFBP-3, and to evaluate the relationship of these forms with GH therapy. Urine and serum were obtained from 12 prepubertal children with GHD, before and after 6 months of GH therapy, from 30 prepubertal healthy children, and from 8 healthy adults. Western immunoblotting (WIB) with IGFBP-3 antiserum (alpha IG-FBP-3g1) showed that in urine the most representative IGFBP-3 was a 17.7-kDa form. The 17.7-kDa IGFBP-3 was high in urine of healthy children compared with healthy adults and was low in children with GHD but increased after GH therapy. Urinary IGFBP-3 immunoreactive profile was determined by neutral-size exclusion chromatography, followed by IGFBP-3 RIA analysis of the fractions. Urine showed a major peak of IGFBP-3 immunoreactivity around 17 kDa. The 17-kDa urinary IGFBP-3 chromatographic peak averaged 8461 +/- 367 ng/12 h.m2 of body surface in healthy children, 3415 +/- 739 in adults (P < 0.001), 2294 +/- 354 in children with GHD before GH therapy (P < 0.001), and 7940 +/- 1874 in children with GHD after GH therapy. Urinary IGFBP-3 was also measured by RIA in unfractionated urine; healthy children showed levels significantly higher (14575 +/- 460 ng/12 h.m2) than adults (7823 +/- 1083, P < 0.001) and higher than children with GHD before GH therapy (4710 +/- 703, P < 0.001). Again, however, immunoreactive IGFBP-3 increased after GH treatment (12294 +/- 3394). In the serum of the healthy children we characterized by specific IGFBP-3 WIB analysis, a 17.7-kDa immunoreactive form of IGFBP-3 that was absent in the serum of healthy adults and low in patients with GHD, increased during GH therapy. Serum samples were subjected to neutral-size exclusion chromatography and the fractions were analyzed by WIB.(ABSTRACT TRUNCATED AT 400 WORDS)
- 1 December 1995
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 80 (12) , 3668-3676
Characterization of a low molecular mass form of insulin-like growth factor binding protein-3 (17.7 kilodaltons) in urine and serum from healthy children and growth hormone (GH)-deficient patients: relationship with GH therapy.
The insulin-like growth factor binding proteins (IGFBPs) are the carriers for insulin-like growth factor (IGF0-I and IGF-II. IGFBP-3 is GH-dependent and circulates associated with IGFs and an acid-labile subunit to form a 150-kilodalton (kDa) complex. In human serum, two immunoreactive molecular weight forms of IGFBP-3 have been identified. In human urine, radioimmunoassayable levels of IGFBP-3 have been detected. The objectives of this study were to characterize the molecular weight forms of IGFBP-3 in urine and serum of healthy children and adults and in children with GH deficiency (GHD), to quantify the urinary molecular weight forms of IGFBP-3, and to evaluate the relationship of these forms with GH therapy. Urine and serum were obtained from 12 prepubertal children with GHD, before and after 6 months of GH therapy, from 30 prepubertal healthy children, and from 8 healthy adults. Western immunoblotting (WIB) with IGFBP-3 antiserum (alpha IG-FBP-3g1) showed that in urine the most representative IGFBP-3 was a 17.7-kDa form. The 17.7-kDa IGFBP-3 was high in urine of healthy children compared with healthy adults and was low in children with GHD but increased after GH therapy. Urinary IGFBP-3 immunoreactive profile was determined by neutral-size exclusion chromatography, followed by IGFBP-3 RIA analysis of the fractions. Urine showed a major peak of IGFBP-3 immunoreactivity around 17 kDa. The 17-kDa urinary IGFBP-3 chromatographic peak averaged 8461 +/- 367 ng/12 h.m2 of body surface in healthy children, 3415 +/- 739 in adults (P < 0.001), 2294 +/- 354 in children with GHD before GH therapy (P < 0.001), and 7940 +/- 1874 in children with GHD after GH therapy. Urinary IGFBP-3 was also measured by RIA in unfractionated urine; healthy children showed levels significantly higher (14575 +/- 460 ng/12 h.m2) than adults (7823 +/- 1083, P < 0.001) and higher than children with GHD before GH therapy (4710 +/- 703, P < 0.001). Again, however, immunoreactive IGFBP-3 increased after GH treatment (12294 +/- 3394). In the serum of the healthy children we characterized by specific IGFBP-3 WIB analysis, a 17.7-kDa immunoreactive form of IGFBP-3 that was absent in the serum of healthy adults and low in patients with GHD, increased during GH therapy. Serum samples were subjected to neutral-size exclusion chromatography and the fractions were analyzed by WIB.(ABSTRACT TRUNCATED AT 400 WORDS)
- 1 January 1993
- Vol. 15 (1) , 111-4
[Multiple pterygium syndrome: description of a new clinical case].
Multiple Pterygium Syndrome is a rare autosomal recessive disorder characterized by short stature, multiple pterygium, joint contractures, vertebral fusions and minor facial anomalies. Due to the extreme phenotypic variability of this syndrome many mild cases may be misdiagnosed or not recognized. The importance of an early diagnosis is to provide an adequate follow-up of these children in order to try to prevent many of the clinical problems they may encounter in their life-time.
- 1 January 1993
- Vol. 15 (1) , 111-4
[Multiple pterygium syndrome: description of a new clinical case].
Multiple Pterygium Syndrome is a rare autosomal recessive disorder characterized by short stature, multiple pterygium, joint contractures, vertebral fusions and minor facial anomalies. Due to the extreme phenotypic variability of this syndrome many mild cases may be misdiagnosed or not recognized. The importance of an early diagnosis is to provide an adequate follow-up of these children in order to try to prevent many of the clinical problems they may encounter in their life-time.